Who Owns Viridian Therapeutics Stock?
NASDAQ: VRDNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 126.76%
- Institutions (% of float)
- 126.97%
- Held by insiders
- 0.17%
- Institutional holders
- 297
- Institutions 99.8%
- Insiders 0.2%
- Public and other 0.0%
Who owns Viridian Therapeutics stock?
Institutional investors own about 126.8% of Viridian Therapeutics's shares, spread across 297 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.17% of VRDN.
The largest institutional holders are FMR, LLC (14.66%), Blackrock Inc. (7.55%) and Bellevue Group AG (5.94%). Together, the top 10 institutions control 62.0% of shares outstanding. In their latest filings, 10 of the top 10 institutions increased their VRDN positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of VRDN
| Institution | Shares | % Held | Change |
|---|---|---|---|
| FMR, LLC | 16.60M | 14.66% | +8.0% |
| Blackrock Inc. | 8.55M | 7.55% | +9.2% |
| Bellevue Group AG | 6.73M | 5.94% | +0.1% |
| Paradigm Biocapital Advisors LP | 6.72M | 5.93% | +113.5% |
| Kynam Capital Management, LP | 6.45M | 5.70% | +175.6% |
| State Street Corporation | 6.12M | 5.41% | +31.1% |
| Price (T.Rowe) Associates Inc | 5.75M | 5.07% | +79.3% |
| Fairmount Funds Management LLC | 5.09M | 4.49% | +30.1% |
| Vanguard Capital Management LLC | 4.58M | 4.04% | +9.8% |
| Deep Track Capital, Lp | 3.59M | 3.17% | +157.7% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of VRDN
| Fund | Shares | % Held |
|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 4.13M | 3.65% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.34M | 2.95% |
| iShares Trust-iShares Russell 2000 ETF | 2.31M | 2.04% |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.78M | 1.57% |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.50M | 1.32% |
| T. Rowe Price Health Sciences Fund, Inc. | 1.45M | 1.28% |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.40M | 1.23% |
| T. Rowe Price New Horizons Fund, Inc. | 1.35M | 1.19% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.31M | 1.15% |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.27M | 1.12% |
Frequently asked questions
Who is the largest shareholder of Viridian Therapeutics?
FMR, LLC is the largest institutional shareholder of VRDN, owning 14.66% of shares outstanding (16.60M shares) as of its latest 13F filing.
What percentage of Viridian Therapeutics is owned by institutions?
Institutions own about 126.8% of VRDN shares and 127.0% of the public float.
How much of Viridian Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.17% of VRDN shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.